Last updated on September 2017

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus


Brief description of study

The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.

Detailed Study Description

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled extension study to characterising the long term safety and tolerability of of an intravenous treatment regimen of anifrolumab versus placebo in subjects with moderately to severely active systemic lupus erythematosus who completed a Phase 3 study (D3461C00004 or D3461C00005) through the 52-week double-blind treatment period.

Clinical Study Identifier: NCT02794285

Contact Investigators or Research Sites near you

Start Over

AstraZeneca Clinical Study Information Center

Research Site
Nadarzyn, Poland
7.3miles
  Connect »